Last reviewed · How we verify
NCT07103629: Filling gap
Bringing Knowledge About Chronic Kidney Disease in Brazil: Filling the Gap
trial in Renal Insufficiency, Chronic in 8,428 participants. Completed in 30 September 2025.
30 September 2025
Quick facts
| Lead sponsor | AstraZeneca |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 8,428 |
| Start date | 31 May 2025 |
| Primary completion | 30 September 2025 |
| Estimated completion | 30 September 2025 |
| Sites | 1 location across Brazil |
Conditions studied
- Renal Insufficiency, Chronic — all drugs for Renal Insufficiency, Chronic →
Sponsor
AstraZeneca — full company profile →
Who can join
Eligibility, any sex, with Renal Insufficiency, Chronic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multicenter cross-sectional study will randomly screen kidney function in adult patients with known risk factors for chronic kidney disease (CKD) within the Brazilian general population. Kidney function will be assessed using a point-of-care creatinine test at local healthcare facilities. Patients with abnormal test results will be referred for laboratory confirmation within three months and will undergo evaluation by the local nephrology team to determine the need for follow-up care.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07103629
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Renal Insufficiency, Chronic
Currently open trials in the same condition.
- NCT07522944 — AI-Guided Relaxation for Hemodialysis Anxiety · NA · recruiting
- NCT07447375 — Exercise During Hemodialysis: Impact on Sarcopenia and Sleep Quality · NA · recruiting
- NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
- NCT07292311 — Reliability of Muscle Strength and Activation Assessment Tools and Effects of an Online Therapeutic Exercise Program in · NA · active not recruiting
- NCT06863194 — Probiotic Supplementation and Disease Progression in CKD: A Randomized Trial · Phase 1, PHASE2 · recruiting
Other AstraZeneca trials
Trials by the same sponsor.
- NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
- NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
- NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
- NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
- NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07103629 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
- Last refreshed: 8 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07103629.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing